INC Research Announces Partnership with Society for Clinical Research - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
INC Research Announces Partnership with Society for Clinical Research

Source: Company News Release

INC Research, a leading, global Phase I to IV clinical research organization (CRO), today announced a two-year partnership with the Society for Clinical Research Sites (SCRS), the first and only global trade organization fully dedicated to representing the interests of clinical research sites. The Company will participate as a Global Impact Partner (GIP), the highest level of membership within SCRS. This move further underscores INC’s continued focus on and commitment to this key stakeholder group, which plays a pivotal role in bringing new therapies to market.

“We’re excited to become an active voice in a community that fully recognizes and supports the critical role of sites in the clinical development process,” said INC Research CEO Jamie Macdonald. “Developing and maintaining quality relationships with investigative sites around the world is a critical success factor to accelerating the delivery of new medicines to market. Joining SCRS is one more way INC Research can demonstrate our commitment to sites by actively collaborating with industry stakeholders on initiatives aimed at establishing best site practices.”

“SCRS is proud to partner with INC Research,” said SCRS President, Christine Pierre. “Collaboration with leading organizations across the clinical research landscape is a pivotal strategic platform for SCRS. This commitment by INC Research speaks to their strong desire to better understand the sites’ perspective, hear their voice and grow closer to the core of the research process.”

As a Global Impact Partner (GIP), INC will participate on the SCRS Global Impact Board at an executive level. Working in tandem with SCRS’ Leadership Council, the Board helps set strategic initiatives for the Society, which advocates, connects, educates, and mentors more than 1,400 sites represented across 22 countries. By providing its members the ability to participate in discussions and decisions, the organization helps to give sites a stronger, more credible voice and a shared purpose within the global clinical research community.

INC Research is focused on connecting customers, sites and patients to improve world health. Ranked the “Top CRO to Work with” in the 2013 CenterWatch Global Investigative Site Relationship Survey of more than 2,000 sites globally, the Company is committed to developing and nurturing deep site relationships that ensure rapid study start-up, smooth study conduct and consistently excellent results. For more information, see our Site Relationships fact sheet.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here